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(http://creativecommoadult population and poses a major health burden with high socioeconomic costs. So far, attempts
to find pharmacologic interventions that can change the onset or progression of dementia have
been largely unsuccessful, prompting a shift to focus on interventions aimed at modifying risk factors
that occur throughout the life course.
Methods: The Cognitive Function and Ageing Studies, funded by the Medical Research Council,
UK, convened three multidisciplinary groups of experts, expert witnesses, and advocates to discuss
the state of evidence on primary, secondary, and tertiary dementia prevention and recommend future
direction for intervention studies.
Results: Using the United Kingdom Parliamentary Select Committees’ approach to gathering evi-
dence, the primary prevention working group focused their deliberation on risk factors strongly asso-
ciated with dementia. The group highlighted the need for high-quality studies to assess the effects of
behavioral intervention on the delay of cognitive decline and dementia onset.
Discussion: The working group recommended that the development of a future dementia prevention
trial should use a multimodal, multifactor, multilevel, community and individually tailored approach.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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Globally, dementia is the most frequent form of degenera-
tive condition in the older adult population and poses a major
health burden with high socioeconomic costs [1]. In 2010, 35
million people were estimated to be living with dementia
worldwide at a cost of over 600 billion USD [1]. Attempts to
find a cure have been largely unsuccessful, prompting a shift
to focus on interventions aimed at modifying risk factors that
occur throughout the life course [2–5]. The Cambridger of the collaboration for leadership in applied health
the east of England (CLAHRC EoE), the Cambridge
Centre infrastructures, Nottingham City and Notting-
Primary care trusts, and the UK NIHR Biomedical
geing and age-related disease award to Newcastle-
undation trust.
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he Authors. Published by Elsevier Inc. on behalf of the Alzh
ns.org/licenses/by/4.0/).Institute of Public Health is one member of ongoing
international collaborations committed to repurposing
existing population cohort studies of late middle age to
older age groups to investigate dementia prevention. Such
international collaborative projects to date include
EURODEM, 21st Century EURODEM, EU–HATICE
(Healthy Ageing Through Internet Counselling in the
Elderly, www.hatice.eu), The European Dementia Prevention
Initiative, and European Prevention of Alzheimer’s disease.
In this article, we present findings and recommendations
from the dementia primary prevention working group based
at the Institute and conclude with a consideration of
challenges facing the design of prevention trial design.2. Methods
Between December 2013 and May 2014, the Cognitive
Function and Ageing Studies (CFAS), funded by theeimer’s Association. This is an open access article under the CC BY license
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multidisciplinary groups of experts, expert witnesses, and
advocates to discuss the state of evidence on primary, sec-
ondary, and tertiary prevention of dementia and recommend
future directions for intervention studies [6]. These work-
shops were conceived from a series of deliberations by a na-
tional collaboration of UK-based institutions to evaluate the
current state of knowledge on a dementia prevention and
intervention strategy. The CFAS are large UK-based longitu-
dinal multicentre studies looking at health and cognitive
decline in those who are aged .65 years [6]. The MRC-
CFAS Prevention Working Groups (CFAS-PWG) are multi-
disciplinary and composed of experts and advocates in the
dementia research field, including representation from disci-
plines such as epidemiology, biostatistics, psychiatry, neuro-
pathology, psychology, social sciences, and translational
medicine (Supplementary Data). The primary prevention
working group adopted the method of the Select Committees
of the Houses of Parliament in the UK. This included a wit-
ness approach with requests for written and verbal evidence,
Skype, or in-person interview where possible on a particular
topic. Information gathered from witnesses was transcribed.3. Summary of evidence
Epidemiological studies have reported consistent find-
ings on modifiable risk and protective factors associated
with the development of dementia [7–11]. Many of these
risk factors are shared with other noncommunicable
conditions (cardiovascular diseases, cancer, and diabetes),
for which cost-effective preventive interventions are
currently sought [12]. Therefore, the CFAS-PWG focused
their deliberation on risk factors most strongly associated
with dementia, namely cognitive activity, physical activity,
social engagement, diet and nutrition, medication optimiza-
tion, vascular risk reduction, mental health, and stress. Most
evidence for associations comes from observational studies,
with a small number of randomized controlled trials present-
ing evaluations of intervention approaches, often with sig-
nificant quality limitations [13].3.1. Single-domain intervention
The evaluation of single-component interventions in the
prevention of cognitive decline and dementia presents a
mixed picture, with a few positive results and many studies
proving ineffective [14–17]. The benefits of physical activity
for noncognitive aspects of health and quality of life in the
older population are well documented, but there is limited
evidence on the effect of physical activity in delaying the
onset of cognitive decline or dementia onset [16,18].
Systematic reviews of intervention studies suggest that
strengthening exercises, aerobic exercises, or a
combination of these show promising preventative effects
on cognitive decline in older people [19,20]. However,
many of the primary studies reviewed lack statisticalpower and their results are inconclusive [20,21]. The effect
of cognitive training on the trajectory of cognitive decline
and dementia is also unclear [17,18]. Although some
studies show promising results, more rigorous trials are
still needed [22,23].
Cardiovascular risk factors including hypertension and
hypercholesterolemia, together with diabetes mellitus and
obesity, are associated with increased risk of dementia,
whereas treatment of hypertension and hypercholesterolemia
is associated with a decrease in incident dementia [24].
Although there is some evidence that controlling hyperten-
sion and systolic blood pressure could be associatedwith pre-
venting cognitive decline inmidlife, there is limited evidence
on the effect of treating vascular risk factors to prevent cogni-
tive impairment or dementia in late-life [25–27]. There is a
dearth of quality studies on the effects of interventions
addressing medication management, social engagement,
and lifestyle factors such as smoking cessation and altered
alcohol intake on the risk of developing dementia, although
observational studies have demonstrated that these factors
are associated with dementia risk [4,10,11,28,29].
A systematic review of intervention studies evaluating
whether diet or nutritional factors can help to prevent cogni-
tive decline found that omega-3 (n-3) polyunsaturated fatty
acids supplementation might be effective in the prevention
of dementia [30]. The evidence on the effect of antioxidants
and B vitamin supplements is less promising, while the ef-
fects of healthy diets such as the Mediterranean diet need
to be confirmed in intervention studies [30–33]. There is
good evidence to show that behavioral interventions
addressing potentially modifiable lifestyle risk factors offer
the possibility of reducing risk of cognitive decline, but
CFAS-PWG acknowledges that there is as yet insufficient
evidence from high-quality trials to permit a firm conclusion
on their effects.3.2. Multimodal intervention
Dementia is a complex syndrome that affects a heteroge-
neous population and carries various risk factors. Therefore,
trials which target multiple domains in combination are
likely to be more effective than those that use single-
component interventions [3]. To date, only a few multido-
main or multi-intervention trials have evaluated the effects
of behavioral interventions on dementia prevention. There
are three ongoing large dementia prevention trials in Europe.
The Prevention of Dementia by Intensive Vascular Care
study is a cluster randomized controlled trial (RCT) evalu-
ating the effect of multicomponent nurse-led vascular care
versus usual care in the nondemented middle-old [34]. The
primary outcomes are incident dementia and disability. The
Multidomain Alzheimer Preventive Trial is a RCT aimed at
evaluating the effects of multicomponent intervention on
change in cognitive function in the middle- to old-old with
subjective memory complaints [35]. The Finnish Geriatric
Intervention Study to Prevent Cognitive Impairment and
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delivered using a combination of individual and group ses-
sions on cognition in at-risk young- to middle-old [36].
The FINGER 2-year results found a positive effect of the
multicomponent intervention on change in cognitive func-
tion. Estimated mean change in neuropsychological test bat-
tery (NTB) total z-score at 2 years was 0.2 (standard error
[SE], 0.01; standard deviation [SD], 0.51) in the intervention
group and 0.16 (SE, 0.01; SD, 0.51) in the control group
[37]. FINGER also found that after 2 years, participants in
the control group increased their risk of cognitive decline
compared with those in the intervention group (NTB, odds
ratio, 1.31; 95% confidence interval, 1.01–1.71). However,
the overall effects of multimodal interventions need to be
disentangled to understand the contribution of individual
components. Given the available evidence on multiple treat-
ment interactions and effects, the CFAS-PWG experts rec-
ommended that a multimodal intervention approach
addressing the aforementioned domains is likely to be
more effective compared with single-domain treatment.4. Discussion
4.1. Multilevel, multicomponent, and individually tailored
Due to the complexity of dementia prevention, the
CFAS-PWG recommend that dementia trial designs should
be tailored to the needs of individuals and communities
and the relevant risk factors, and both initiated and evaluated
at individual, household, and community levels. The hetero-
geneity of the older population based on risk factors and age
and possibly biomarkers should be considered explicitly,
with the goal of finding the best intervention for individuals
defined by these characteristics [2]. The target participant
groups for preventive efforts would range from the healthy
and optimally functioning to thosewithmultiple health prob-
lems and those with cognitive impairment and dementia.
Individual-level interventions should focus on ways to
optimize and maintain healthy functioning. A modular
approachmay be taken to address different risk and protective
factors, acknowledging that participants’ needs will differ.
For example, some people might benefit from simple provi-
sion of information, whereas others might need a more inten-
sive approach. Having people actively identify what they
need to or are willing to do is also important. For example,
a community facilitator could signpost people to particular
resources or activities. Here again, the comparison might be
between an active goal-setting approach and simple provision
of information. Furthermore, individual-level interventions
for the high-risk groups could include a HATICE-style inter-
vention combined with medication management.
A household-level intervention would ideally involve
working with everyone in the household to identify
environmental modifications and other changes that could
be made. Practical examples include taking televisions out
of the bedrooms, removing remote controls to promotemovement, or introducing smaller plates to reduce portion
size. The CFAS-PWG group recognizes that it is important
not to be seen as imposing changes, but rather to help people
to internalize or “own” the changes they wish to make.
Finally, community-level interventions would involve
working with local authorities to identify localities (streets,
neighborhoods, or deprivation areas) where initiatives can be
developed to encourage more physical and cognitive activity
and social engagement. The CFAS-PWG group recom-
mends that a cluster RCT would be most appropriate form
of evaluation for these interventions.4.2. Other challenges
The CFAS-PWG highlighted the need for quality studies
to assess the effects of behavioral intervention on the delay
of cognitive decline and dementia onset. To achieve this,
study designs need to be RCTs or adaptive trials, have larger
samples, cover a sufficiently long follow-up period, and
identify the most appropriate outcome measures [13]. As
prevention of dementia would be a distal outcome, it is
important to focus on a range of behavioral outcomes
demonstrating changes that may be associated with reduced
risk. For example, the FINGER study has shown that change
in cognitive function is a sensitive enough measure for use as
a proximal and a distal outcome in future trials [37]. It is also
important to consider what factors will motivate participants
to engage in interventions. Offering the opportunity to
improve health and well-being in the short to medium
term may be more engaging and motivating than offering in-
terventions to reduce the risk of developing dementia in the
future. In addition to agreeing on standardized outcomes for
dementia prevention, there is a further need to form a
consensus on the optimal “dose” or intensity of interventions
required to detect significant effects [18]. Failing this,
research in this area could be open to multiple interpretations
with the risk of failing to detect positive effects of potentially
worthwhile approaches [18]. Other practical challenges
cited by the CFAS-PWG included securing funding,
designing affordable and translatable interventions, and
how to best collaborate across countries and studies.5. Conclusion
The limited evidence available about reducing the risk of
developing dementia, coupled with the strong and growing
interest in this topic, presents an important opportunity.
The CFAS Dementia Primary Prevention Working Group
looked at evidence available at the time of meeting (2014)
and proposed a holistic approach to designing a dementia
prevention trial. A summary of the group’s evidence review
is presented using an evidence synthesis matrix (Table 1).
Thework embodied several key principles including sustain-
ability, feasibility, potential for wider implementation at
community and household levels, and an individual perspec-
tive. The core recommendation is that the development of
Table 1
Primary prevention working group evidence synthesis matrix
Modality
Cognitive activity—
thinking
Physical activity—
moving
Social engagement—
mixing
Diet and nutrition—
eating and drinking
(including other
lifestyle factors)
Medication
optimisation
Physical health
(vascular risk
reduction)
Mental health—
mood
Well-being—stress
reduction
Individual
in-person
Evidence from RCTs
of specific
cognitive training
or cognitive
activity [17]. Some
studies provide
evidence of benefits
to cognition.
Advanced
Cognitive Training
for Independent
and Vital Elderly
Study [23] provides
evidence of
generalisation to
everyday
functioning.
Quality of evidence
generally low.
Evidence from RCTs
of physical exercise
interventions.
Some studies find
benefits to
cognitive function
[19,38]. Quality of
evidence generally
low.
No evidence from
intervention trials.
Evidence from RCTs
suggests that
adherence to
Mediterranean diet
may reduce risk but
dietary
supplementation is
not effective [30].
Quality of evidence
generally poor.
No direct evidence
that smoking
cessation delays or
prevents dementia.
No evidence from
intervention trials
regarding alcohol
intake. MAPT to
report soon [35].
No evidence that
particular
medications protect
against or prevent
dementia. Evidence
for harmful effects
of polypharmacy
from observational
studies.
Limited evidence to
date but PreDIVA
trial will report in
2015 [34]
One study suggests
that long-term
treatment with
tricyclics or
monoamine
oxidase inhibitors
(but not selective
serotonin reuptake
inhibitors) may
reduce incidence of
dementia [39].
No evidence from
intervention
trials.
Internet based Internet based or
computerized
interventions are
regarded as
offering promising
effects.
— — — — — — —
Immediate
network/
community
Some cognitive
activity
interventions at this
level report benefits
to cognition [40].
Environmental
modification
approaches
suggested—no
research evidence.
Some activity-
based interventions
operate at this level.
Some activity-based
interventions at this
level include social
support/social
networks.
Environmental
modification
approaches
suggested – no
research evidence.
— — — —
Wider
community
— — — Policy interventions
suggested—no
research evidence
— — — —
Abbreviations: RCT, randomized controlled trial; MAPT, MultiDomain Alzheimer Preventive Trial; PreDIVA, Prevention of dementia by intensive vascular care.
NOTE. Thematrix table is populated with a brief summary of evidence considered by the Primary PreventionWorking group. The rows represent potential areas of delivery for interventions, whereas the entries
in the columns give a summary of evidence for each mode of intervention.
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multifactor, multilevel, as well as individually tailored ap-
proaches.
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1. Systematic Review: This was an expert review by the
MRC-CFAS Prevention Working Groups (CFAS-
PWG), which gathered evidence using the method
of the Select Committees of the Houses of Parliament
in the United Kingdom. This included a witness
approach with requests for written and verbal evi-
dence, or Skype or in person interview where
possible on a particular topic. Much of the evidence
used during deliberation was compiled using avail-
able systematic reviews, supplemented where appro-
priate by opinion from narrative reviews and by
details of individual studies. Individual studies
were either already known or were identified by
expert witnesses.
2. Interpretation: This review highlighted the need for
high quality studies to assess the effects of behaviou-
ral intervention on the delay of cognitive decline and
dementia onset.
3. Future Directions: The working group recommended
that the development of future dementia prevention
trial should use a multi-modal, multi-factor, multi-
level, and individually tailored approach.References
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